Skip Navigation

Phase I/Expansion Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma

Brief Summary

Type:
Lymphomas

Study Type:
Treatment

Phase:
I

ClinicalTrials.gov Identifier:
NCT05627245

Study #:
STUDY00149926

Start Date:
May 16, 2023

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05627245

View Complete Trial Details & Eligibility at ClinicalTrials.gov